Transforming growth factor beta receptor type II frameshift mutant peptide presented on HLA-A*02 (TGFβRII frameshift mutant peptide-HLA-A*02)

The **transforming growth factor beta receptor type II (TGFβRII)** is a membrane receptor involved in TGF-beta signaling, playing a role in regulating cell proliferation, differentiation, and apoptosis. In colorectal and other cancers exhibiting microsatellite instability (MSI), frameshift mutations occur frequently in a polyadenine tract of the TGFβRII gene, resulting in the production of a novel C-terminal peptide sequence not present in normal tissues. This mutant peptide contains a cytotoxic T lymphocyte (CTL) epitope, such as RLSSCVPVA, which can be presented on HLA-A*02 molecules on the tumor cell surface. This makes it a tumor-specific neoantigen recognized by CD8+ T cells, offering a potential target for immunotherapy, particularly cancer vaccines and adoptive T cell therapies in patients with MSI-H tumors harboring the mutation and expressing the appropriate HLA type[1][4][5]. This target is under investigation in the context of personalized and shared neoantigen cancer immunotherapy.

Other names

TGFβRII frameshift neoantigenTGFβRII mutant peptideTGFβRII frameshift epitope (RLSSCVPVA)HLA-A*02-restricted TGFβRII frameshift peptide

Recognition and lysis of tumor cells by CD8+ cytotoxic T lymphocytes specific for the mutant peptide presented by HLA-A*02 molecules[1][5]. Induction of anti-tumor immune response through vaccination or engineered T cell therapies targeting this specific neoantigen[2][5].